Details for Patent: 10,864,194
Which drugs does patent 10,864,194 protect, and when does it expire?
Patent 10,864,194 protects SOHONOS and is included in one NDA.
This patent has twenty-nine patent family members in eighteen countries.
Summary for Patent: 10,864,194
| Title: | Methods for treating heterotopic ossification | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | The invention features dosing regimens and pharmaceutical formulations for oral administration of palovarotene. The dosing regimens can reduce heterotopic ossification, reduce the number of flare-ups, and/or reduce the severity of flare-ups in subjects suffering from fibrodysplasia ossificans progressiva. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Clarissa Desjardins, Donna Roy GROGAN, Jeffrey Neal PACKMAN, Mark Harnett | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Clementia Pharmaceuticals Inc | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US16/308,012 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | United States Patent 10,864,194: Palovarotene Dosing Claims, Patent Scope, Expiration and Generic RiskU.S. Patent No. 10,864,194 protects a flare-up-responsive palovarotene regimen for reducing heterotopic ossification in patients with fibrodysplasia ossificans progressiva, or FOP. The core regimen is 5 mg daily when the patient has no flare-up, followed by 20 mg daily for approximately 28 days after a flare-up begins, then 10 mg daily for up to 112 days. The patent is assigned to Clementia Pharmaceuticals, now part of Ipsen, and is directed to treatment methods rather than palovarotene composition, formulation, or manufacturing claims. The patent has substantial relevance to Sohonos, Ipsen’s FDA-approved palovarotene product. Its commercial strength comes from the close overlap between the claimed regimen and the FDA-approved flare-up dosing schedule. Its principal weakness is claim narrowness: infringement requires proof of the specified patient condition, dosing sequence, timing, flare-up criteria, and, for several claims, patient weight or skeletal maturity. What does U.S. Patent 10,864,194 cover?The patent covers methods of reducing heterotopic ossification in a subject with FOP by using two dosing states:
Independent claim 1 is the broadest principal claim. Independent claim 3 narrows the regimen to the commercially important schedule of 5 mg daily during quiescence, 20 mg daily for 28 days during a flare-up, and 10 mg daily for at least 56 days thereafter.
The claimed dose tolerances translate into the following practical ranges:
The exact-dose language in claim 3 is potentially more restrictive than the tolerance language in claim 1. A regimen using 5 mg, 20 mg, and 10 mg falls within both claim structures, assuming all other limitations are met. How do claims 1 and 3 differ?Claims 1 and 3 are separate independent claims with overlapping but different dosing limitations. Claim 1 permits:
Claim 3 requires:
Claim 3 is narrower in duration but closely tracks the dosing schedule reflected in the Sohonos prescribing information. Claims 20 through 30 depend from claim 3 and add further restrictions involving 56-day treatment, an additional 28 days if symptoms continue, patient weight, antihistamines, emollients, symptom categories, and palovarotene or its salt form. What are the limitations of the dependent claims?The dependent claims create multiple fallback positions.
The weight limitation is commercially significant because the FDA-approved regimen for patients weighing at least 60 kg corresponds closely to the 5 mg chronic dose and 20/10 mg flare-up sequence. The claims do not expressly require a particular sex or age, although the approved indication imposes age and sex restrictions. What is the scope of the flare-up limitation?The claims require treatment during a period when the subject is experiencing at least one flare-up symptom. Claim 17 and claim 28 identify the relevant symptoms as:
This limitation is central to infringement. A product label or clinical protocol that merely recommends palovarotene for FOP without directing the claimed flare-up transition may present a weaker induced-infringement case. Conversely, a label instructing patients to increase the dose after swelling, pain, warmth, or reduced mobility would closely align with the patent claims. The claims do not require a particular diagnostic test, imaging result, anatomical site, or minimum severity threshold for the flare-up. The absence of those limitations broadens the practical trigger for the regimen, although indefiniteness, written-description, enablement, and claim-construction issues could arise if a dispute concerned borderline symptoms. What is the FDA status of palovarotene and Sohonos?The FDA approved Sohonos capsules for reducing the volume of new heterotopic ossification in females aged 8 years and older and males aged 10 years and older with FOP. The product is approved in multiple capsule strengths, including 1 mg, 1.5 mg, 2.5 mg, 5 mg, and 10 mg presentations. The approved dosing instructions include chronic dosing and higher dosing during a flare-up, followed by a lower dose after the initial flare-up period (FDA, 2023). The 5 mg, 20 mg, and 10 mg schedule is most relevant to patients weighing at least 60 kg. The label also contains safety restrictions associated with skeletal maturity and premature epiphyseal closure. These regulatory conditions narrow the practical population even though several patent claims use broader subject language.
The FDA’s approval was based principally on clinical data from the MOVE study and supporting studies evaluating new heterotopic ossification in patients with FOP. What is the Orange Book status of U.S. Patent 10,864,194?U.S. Patent 10,864,194 is associated with the palovarotene product patent estate and is relevant to Orange Book-listed protection for Sohonos. The patent is a method-of-use patent. It does not primarily protect the palovarotene molecule itself or a capsule excipient system. Public patent records identify the patent as:
The terminal expiration date should be distinguished from orphan-drug exclusivity. Patent expiration and FDA regulatory exclusivity arise under separate legal authorities. A generic applicant may face both barriers, and the expiration of one does not automatically terminate the other. When does palovarotene lose exclusivity?Sohonos received orphan-drug exclusivity for FOP. The seven-year orphan-exclusivity period runs from FDA approval and is expected to extend to December 15, 2030 for the approved FOP indication, subject to statutory exceptions such as inability to assure sufficient quantities or the sponsor’s inability to provide the product (FDA, 2023; 21 U.S.C. § 360cc). The principal exclusivity dates are therefore:
Patent protection extends materially beyond orphan exclusivity. A generic applicant could potentially file an abbreviated new drug application before 2037 with a Paragraph IV certification, but commercial launch would create litigation risk if Ipsen sued within the statutory period. What Paragraph IV challenges and patent litigation affect Sohonos?No publicly identified Paragraph IV litigation or settlement involving U.S. Patent 10,864,194 is reflected in the cited FDA and patent records. The absence of a public case does not eliminate future challenge risk. A generic applicant seeking approval before patent expiration could certify that the patent is invalid, unenforceable, or will not be infringed. Ipsen could then bring an infringement action under the Hatch-Waxman framework. A timely suit could trigger a 30-month stay of approval, subject to statutory exceptions and court action. The strongest potential generic arguments would likely focus on:
Ipsen’s strongest counterarguments would be:
How strong is the patent estate for palovarotene?The patent estate is strongest against a generic seeking to copy the FDA-approved FOP dosing instructions. It is less comprehensive against alternative clinical or commercial strategies.
The patent does not prevent every use of palovarotene. A competing product could seek a different disease indication, different dose, different flare-up definition, different duration, or a regimen that avoids one or more claim limitations. Such a product could still face other patents, regulatory barriers, or induced-infringement theories. What formulations are protected by U.S. 10,864,194?The supplied claims do not claim a particular formulation. They cover oral administration of palovarotene or a pharmaceutically acceptable salt. They do not specify:
The formulation claim language is therefore broad as to the dosage form but limited to oral administration. A generic oral palovarotene capsule could fall within the method claims if its label instructs the claimed dosing regimen. A nonoral formulation would not satisfy the express oral-administration limitation. Does the patent create biosimilar risk?No. Palovarotene is a chemically synthesized small molecule, not a biologic. The relevant competitive pathway is an ANDA for a generic drug, not a biosimilar application under the Public Health Service Act. The principal generic barriers are:
What licensing deals affect the patent?Clementia Pharmaceuticals developed palovarotene and was acquired by Ipsen in 2019. The acquisition transferred Clementia’s palovarotene assets, including the FOP development program and associated intellectual property, to Ipsen. Ipsen is the relevant commercial and patent owner for Sohonos in the United States (Ipsen, 2019). No separate public license is necessary to explain Ipsen’s U.S. position. The principal transaction affecting ownership is Ipsen’s acquisition of Clementia. What generic launch scenarios exist?Scenario 1: Launch after patent expirationThis is the lowest-risk scenario. A generic applicant waits until the relevant patent and orphan-exclusivity barriers have expired, subject to any remaining patents or regulatory exclusivities. Scenario 2: Paragraph IV challengeA generic applicant files before April 2037 and alleges that U.S. 10,864,194 is invalid, unenforceable, or not infringed. Ipsen may sue, potentially delaying approval through the Hatch-Waxman litigation process. Scenario 3: Carve-out or skinny labelA generic applicant may attempt to omit patented method-of-use information from its label. This strategy is difficult if the approved indication and dosing instructions inherently direct the 5/20/10 mg regimen. The feasibility depends on FDA labeling requirements and whether the omitted use can be separated from the remaining approved indication. Scenario 4: Noninfringing alternative regimenA competitor could pursue a different dose or flare-up schedule. This approach may avoid literal infringement but would require separate clinical support and FDA approval. It may also encounter other patents in the palovarotene estate. How does U.S. 10,864,194 compare with a composition or formulation patent?A composition-of-matter patent generally provides broader commercial control because it can cover use of the molecule regardless of indication or dose. U.S. 10,864,194 is narrower. It requires a particular disease, therapeutic purpose, oral route, symptom-triggered transition, dose sequence, and treatment duration. Its value is therefore concentrated in the approved FOP regimen. The patent is commercially important because the method claim aligns with product labeling, but it does not independently block every palovarotene product. Key Takeaways
FAQs About U.S. Patent 10,864,194 and PalovaroteneIs U.S. Patent 10,864,194 a patent on Sohonos itself?No. It is principally a method-of-treatment patent covering specified palovarotene dosing regimens for FOP. Does the patent cover palovarotene for every FOP patient?No. Several claims include specific dose sequences and durations. Dependent claims add limitations involving weight, skeletal maturity, flare-up symptoms, antihistamines, and emollients. Can a generic sell palovarotene before 2037?Potentially, but it would need to overcome applicable orphan exclusivity and patent barriers, usually through a Paragraph IV challenge, a successful noninfringement position, or a valid label carve-out. Does a different flare-up dose automatically avoid infringement?No. It may avoid literal infringement of the claimed dose limitation, but the full claim set, equivalents, other patents, and the proposed product label would determine overall exposure. Is palovarotene subject to biosimilar competition?No. Palovarotene is a small-molecule drug. Competition would proceed through the generic-drug framework, principally an ANDA. References
More… ↓ |
Drugs Protected by US Patent 10,864,194
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ipsen | SOHONOS | palovarotene | CAPSULE;ORAL | 215559-001 | Aug 16, 2023 | RX | Yes | No | 10,864,194 | ⤷ Start Trial | REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA | ⤷ Start Trial | ||||
| Ipsen | SOHONOS | palovarotene | CAPSULE;ORAL | 215559-002 | Aug 16, 2023 | RX | Yes | No | 10,864,194 | ⤷ Start Trial | REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA | ⤷ Start Trial | ||||
| Ipsen | SOHONOS | palovarotene | CAPSULE;ORAL | 215559-003 | Aug 16, 2023 | DISCN | Yes | No | 10,864,194 | ⤷ Start Trial | REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,864,194
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2017276835 | ⤷ Start Trial | |||
| Australia | 2022202148 | ⤷ Start Trial | |||
| Brazil | 112018075422 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
